Ovarian Cancer

P2/3, N=360, Not yet recruiting, Shanghai Municipal Hospital of Traditional Chinese Medicine

P1/2, N=20, Enrolling by invitation, Shenzhen Geno-Immune Medical Institute | Suspended --> Enrolling by invitation | Trial completion date: Dec 2020 --> Dec 2028 | Trial primary completion date: Jan 2020 --> Jan 2028

Using a novel phospho-specific monoclonal antibody, we show that TPR is phosphorylated at Ser2155 following EGFR activation via the canonical RAS-RAF-MEK-ERK MAPK cascade, placing TPR downstream of MAPK pathway activation...Finally, immunohistochemical analysis reveals elevated TPR phosphorylation in serous ovarian carcinoma and heterogeneous phosphorylation patterns in triple-negative breast cancer, two tumor types frequently characterized by MAPK pathway hyperactivation. Together, these findings uncover a previously unappreciated role for TPR as a MAPK-responsive nuclear factor and support a model in which NPC-associated components fine-tune mitogen-induced transcriptional responses.

The combination of anticancer therapies with GPX4 inhibitors eliminated senescent tumour cells in models of melanoma, prostate and ovarian cancer. Our results show that senescent cells rely on GPX4 to prevent ferroptosis and that GPX4 inhibitors kill senescent cells.

This study elucidates the mechanism by which the ROS-c-JUN-USP18-IGF2BP2-FSP1 axis regulates cisplatin resistance and proposes a novel iFSP1-cisplatin combination therapy, offering a promising new strategy for OC treatment.

P=N/A, N=48, Active, not recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Aug 2026

P=N/A, N=6465, Recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N=1300 --> 6465 | Trial primary completion date: Apr 2024 --> Dec 2026

A trial of the PARP inhibitor niraparib was initiated, but the patient deteriorated rapidly and died 6 weeks after presenting with headache...This case posed challenges both in diagnosis and in management, with limited evidence available to guide choice of therapy. Unfortunately, the response to PARP inhibitor in this patient could not be assessed due to her rapid deterioration.

PFI, histological subtype, PS, and CA125 levels are important prognostic factors for the use of molecular-targeted agents for recurrent epithelial ovarian cancer. Patients with CC and EM subtypes experience worse outcomes than those with HGS, highlighting the need for subtype-specific management in recurrent ovarian cancer.